Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration

ZHE ZHANG$^{1,2}$, JING-HUA REN$^2$, ZHEN-YU LI$^2$, LI NONG$^2$ and GANG WU$^2$

$^1$Department of Integrated Therapy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032; $^2$Department of Oncology, The Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P.R. China

Received November 11, 2011; Accepted January 17, 2012

DOI: 10.3892/or.2012.1686

Abstract. The aim of this study was to investigate the effect of fasudil on lung carcinoma-conditioned endothelial cells (LCc-ECs). To obtain LCc-ECs, human umbilical vein endothelial cells (HUVECs) were treated with conditioned cell culture media from human A549 lung adenocarcinoma cells. The effect of fasudil on the viability of LCc-ECs was assessed using the MTT assay, in vitro invasive ability was evaluated using the transwell chamber assay and cytoskeletal changes were detected using fluorescein-labelled phalloidin immuno-cytochemistry. RhoA mRNA and p-MLC protein expression were measured using RT-PCR and western blotting. Fasudil significantly and dose-dependently inhibited LCc-EC proliferation and in vitro invasive ability. Fasudil also led to stress fibre breakage and fracture in LCc-ECs, indicating that fasudil impacts polymerisation of the cytoskeletal actin filament network. Expression of RhoA mRNA and protein expression of the ROCK substrate p-MLC were reduced by fasudil, suggesting that fasudil can inhibit Rhoa/ROCK signalling and attenuate angiogenesis in LCc-ECs. This study indicates that fasudil is an anti-angiogenic agent with potential application for the treatment of cancer, especially lung adenocarcinoma.

Introduction

Angiogenesis is the formation of new capillary blood vessels from endothelial or stem cells, and is essential during wound healing, embryonic development and tumorigenesis (1). Angiogenesis is intricately regulated by a number of factors, including the extracellular matrix, growth factors, membrane-bound proteinases and integrins which induce cytoskeleton rearrangement and delicately orchestrate the various steps of angiogenesis, including endothelial cell (EC) proliferation, branching and sprouting and lumen formation (2). Cells migrate by rearranging the actin cytoskeleton (3), and formation of adhesive structures and cellular contraction are essential steps during cell migration. The actin cytoskeleton plays a critical role in the regulation of the complex series of signalling events which lead to EC shape changes during migration and angiogenesis.

Tumour and normal endothelium are distinct at the molecular level. St. Croix et al (4) compared the gene expression patterns of endothelial cells derived from the blood vessels of normal and malignant colorectal tissues. Of over 170 transcripts which are predominantly expressed in the endothelium, 79 were differentially expressed, 46 of which, including TEM1 and TEM8 were specifically elevated in the tumour-associated endothelium.

The small GTPase RhoA and the downstream effector, Rho-kinase (ROCK) play a central role in diverse cellular functions, including smooth muscle contraction, cytoskeleton rearrangement, cell migration, cell proliferation and gene expression (5). Rho-kinase regulates stress fibre formation and cell-cell junctions in ECs in response to vascular endothelial derived growth factor (VEGF) (6). Members of the Rho family of GTPases have also emerged as key players in the regulation of a variety of biological activities involving cell motility and actin cytoskeleton reorganization (7). Several members of this family, including RhoA, Cdc42 and Rac1 are involved in focal adhesion complex assembly, cell polarity, gene transcription and cell-cycle progression (8).

Fasudil (HA-1077), a ROCK inhibitor, has been approved in Japan since 1995 for the clinical treatment of vascular spasms in the brain (9,10). Yin et al (11) showed that fasudil inhibits VEGF-induced angiogenesis in vitro and in vivo. However, the effect of fasudil on lung carcinoma-conditioned endothelial cells (LCc-EC) has not been reported. In this study, we investigated the effect and mechanism of action of fasudil on LCc-EC to explore the potential for the application of fasudil in lung cancer treatment.

Materials and methods

Lung carcinoma-conditioned endothelial cell culture. The A549 lung cancer cell line was obtained from the State Key
Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences (Beijing, China). Human umbilical vein endothelial cells (HUVECs) were prepared and identified as previously described (11). Briefly, undamaged sections of fresh umbilical cords were cannulated, washed in PBS, perfused with trypsin and the detached cells were collected and resuspended in RPMI-1640 medium. A549 cells and HUVECs were cultured in RPMI-1640 medium supplemented with 10% (v/v) foetal calf serum (FCS) at 37°C in 5% CO₂. A549 cell culture supernatant was used to stimulate HUVEC growth to obtain LCC-ECs as previously described (12). Cell culture reagents were purchased from Gibco (Carlsbad, CA, USA) and collagen type I was purchased from Sigma (St. Louis, MO, USA).

Cell viability assay. Briefly, LCC-ECs were plated in 96-well plates, allowed to attach, and made quiescent. Cells were treated with fasudil (Sigma) for 1 h, and the number of viable cells was determined by addition of MTT solution for 2 h and measuring the absorbance at 630 nm as previously described (13). The experiments were performed in triplicate.

Cell migration assay. LCC-EC migration was analysed using the Boyden chamber assay. Briefly, LCC-ECs were resuspended at 1x10⁴ cells/ml in RPMI-1640 media without or with 0, 20, 40, or 70 µmol fasudil and 300 µl aliquots of cell suspension were seeded into the matrigel-coated upper chamber of 8.0 µm pore size Boyden chamber inserts (Becton-Dickinson, Franklin Lakes, NJ, USA). The chambers were inserted into the wells of 24-well plates coated with fibronectin and containing 700 µl RPMI-1640 and 1 ml NIH/3T3 fibroblast-conditioned medium as a chemoattractant. After 24 h incubation, the cells in the upper layer were swabbed with cotton, and cells which had migrated to the lower layer of the chamber were fixed in 95% ethanol and stained with hematoxylin. The number of cells which migrated through each membrane were counted using light microscopy (14).

Immunocytochemistry. The actin filaments in LCC-ECs were visualized by immunocytochemistry using a rhodamine-labelled anti-phalloidin antibody (Sigma). Briefly, fasudil-treated or untreated LCC-ECs were seeded on cover-slips, fixed in 3.7% formaldehyde for 10 min at room temperature and incubated in 0.1% Triton X-100 in PBS (pH 7.4) for 5 min (13). To reduce non-specific background staining, the cells were incubated for 30 min with PBS containing 1% bovine serum albumin (BSA) prior to addition of antibody (15,16). The images were recorded and analyzed using a Zeiss confocal photomicroscope LSM510 (Zeiss).

Reverse transcription PCR. Total RNA was isolated from LCC-ECs using TRizol reagent (Invitrogen) according to the manufacturer's instructions and used for reverse transcription PCR following standard techniques with specific primers for TEM8 (forward: 5'-CGGATTGGGACGATAGG-3'; reverse: 5'-GCCGAACACCGAGGAG-3'), TEM1 (forward: 5'-TGGATTTATTGTAGCCGAGGACATG-3'; reverse: 5'-AGGTGGGACCCGGAGGTGATT-3'), RhoA (forward: 5'-GTGATTTGGTGATGGAGGC-3'; reverse: 5'-CTCCGTG GCCATCTCAAAAC-3') and GAPDH as a control (forward: 5'-ACCACAGTCCATGCCCATCAC-3'; reverse: 5'-TCCACCA CCCCCGTTGCTTGA-3'). The PCR products were separated by electrophoresis on 1.5% agarose gels, visualized by ethidium bromide staining.

Western blot analysis. Untreated or fasudil treated LCC-ECs were lysed and centrifuged at 10,000 rpm for 5 min at 4°C (17,18). Protein concentrations were determined using the Bio-Rad protein assay system (Applied Biosystems, Foster City, USA) with BSA as a standard (19). The lysates were resolved by 12% SDS-PAGE and transferred to 0.2 µm nitrocellulose membranes (20). Western blot analysis was performed using a monoclonal anti-human p-MLC antibody. Bands were visualized using autoradiography, the band intensities were quantified using BioMax Image Analysis software (Applied Biosystems) and protein expression levels were normalized to GAPDH.

Statistical analysis. Differences between groups were analyzed by one-way ANOVA using SPSS 13.0 (SPSS, Chicago, IL, USA); P<0.05 were considered statistically significant.

Results

Characteristics of LCC-ECs. Immunofluorescence staining confirmed that factor VIII related antigen (VIIIrAg) is expressed in LCC-ECs (Fig. 1A) showing that LCC-ECs possess endothelial cell features. Using RT-PCR we detected that TEM1 (287 bp) and TEM8 mRNA (462 bp), were expressed at high levels in LCC-ECs (Fig. 1B and C) compared to control HUVECs, indicating that LCC-ECs possess tumour-associated endothelial cell characteristics.

Fasudil reduces LCC-EC viability. Fasudil has been used to treat vascular spasms in the brain in Japan since 1995 (9,10); however, the mechanism by which fasudil affects tumour angiogenesis has not been delineated. Therefore, we investigated the effect of fasudil on LCC-ECs in vitro. The MTT assay indicated that fasudil treatment significantly inhibited the viability of LCC-ECs in a dose-dependent manner after 96 h (Fig. 2). The IC₅₀ for fasudil at 24 h in LCC-ECs was 84±4.6 µmol.

Fasudil inhibits LCC-EC migration. Cell migration is a critical step in the process of angiogenesis (21). Therefore, we evaluated the effects of fasudil treatment on the migration of LCC-ECs using in vitro migration assays. Treatment with fasudil significantly suppressed LCC-EC migration in a dose-dependent manner (Fig. 3).

Fasudil treatment inhibits stress fibre formation in LCC-ECs. Cell migration begins with an initial protrusion or extension of the plasma membrane at the leading edge of the cell. The protrusion is driven by the polymerization of a network of cytoskeletal actin filaments and is stabilized through the formation of adhesive complexes (22). To investigate whether fasudil can prevent LCC-EC migration by affecting actin cytoskeletal organization, actin stress fibres were visualized by immunocytochemistry. Compared to control cells, treatment with fasudil led to stress fibrebreakage and fracture in
LCc-ECs (Fig. 4), indicating that fasudil impacts polymerisation of the cytoskeletal actin filament network.

**Fasudil reduces expression of RhoA mRNA in LCc-ECs.** We examined the expression of RhoA mRNA in LCc-ECs treated with 0, 20, 40 and 70 µmol fasudil using RT-PCR. Fig. 5 shows that the expression of RhoA was significantly inhibited by fasudil in a dose-dependent manner.

**Fasudil suppresses ROCK functionality in LCc-ECs.** LCc-ECs were untreated or treated with fasudil for 1 h and western blot analysis was performed to determine the expression of the ROCK substrate p-MLC. Fasudil treatment significantly reduced the protein expression levels of p-MLC in a dose-dependent manner (Fig. 6).
To date, there have been no studies on the effects and mechanism of action of fasudil in lung carcinoma-conditioned endothelial cells (LCc-ECs). In this study we derived LCc-ECs from HUVECs using A549 lung cell carcinoma-conditioned
media as a model of lung tumour endothelial cells. VIIIIRAg staining of LCc-ECs confirmed that the cells were endothelial cells. Tumour and normal vascular endothelial cells are different at the molecular level. TEM1 and TEM8 mRNA expression characteristically increase in tumour-associated endothelial cells (4). We observed that TEM1 and TEM8 mRNA were significantly upregulated in LCc-ECs, compared to control HUVECs, indicating that LCc-ECs had acquired tumour endothelium characteristics.

In this study, fasudil treatment significantly inhibited the viability of LCc-ECs in a dose-dependent manner. It is well known that cancer progression and metastasis require cell motility (23), and cell migration is a key step in angiogenesis. Fasudil also markedly attenuated LCc-EC cell migration and lead to partial stress fibre breakage and fracture, resulting in a reduced in vitro invasive ability of LCc-ECs.

The GTPase RhoA mediates cell contraction by organizing actin filaments into stress fibres, and active RhoA is required for a variety of complex morphogenetic processes (11). RhoA activates ROCK, which plays an important role in the regulation of actin stress fibre organization (24). Treatment of LCc-ECs with fasudil resulted in altered stress fibre formation; therefore, it is likely that fasudil may affect RhoA/ROCK signalling. Fasudil significantly and dose-dependently reduced expression of both RhoA mRNA and of the ROCK substrate p-MLC. These results indicate that the ability of fasudil to affect LCc-EC viability, invasion and actin polymerisation is linked to attenuated RhoA/ROCK activation and signalling. Further research is required to determine the mechanism by which fasudil inhibits RhoA expression and ROCK activation.

Previous experiments have indicated that RhoA/ROCK critically regulates VEGF-induced angiogenesis. Constitutively active RhoA can synergize with VEGF to stimulate angiogenesis (23), whereas dominant negative RhoA markedly inhibits VEGF-driven neovascularization (25). Thus, the function of RhoA is consistent with a possible role in vascular morphogenesis. ROCK may be a key player in ECs during angiogenesis (26). ROCK mediated angiogenesis plays an important role in tumour progression and metastasis, and is an attractive target for anticancer strategies.

In conclusion, this study demonstrates that fasudil significantly inhibits the viability and invasive ability of LCc-ECs, through a mechanism dependent on disrupted actin cytoskeleton polymerisation which is linked to reduced activation of RhoA/ROCK signalling. This study indicates that the antiangiogenic agent fasudil has potential applications for the treatment of cancer, especially lung adenocarcinoma.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (no. 30973473/H1611).

References


